LXEO Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $4,999,995.00
Insider Selling (Last 12 Months): $0.00

Lexeo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Lexeo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lexeo Therapeutics Share Price & Price History

Current Price: $12.23
Price Change: Price Decrease of -0.83 (-6.36%)
As of 04/12/2024 01:00 AM ET

This chart shows the closing price history over time for LXEO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Lexeo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2023Fund Vi L.P. OmegaMajor ShareholderBuy454,545$11.00$4,999,995.002,157,623View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Lexeo Therapeutics (NASDAQ:LXEO)

60.67% of Lexeo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LXEO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Lexeo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.416,182$5.59M0.0%N/A1.562%Search for SEC Filing on Google Icon
2/20/2024Eventide Asset Management LLC3,002,831$40.30M0.7%N/A11.268%Search for SEC Filing on Google Icon
2/15/2024Legal & General Group Plc15,000$0.20M0.0%N/A0.056%Search for SEC Filing on Google Icon
2/15/2024Barclays PLC15,517$0.21M0.0%N/A0.058%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.416,182$5.59M0.0%N/A1.562%Search for SEC Filing on Google Icon
2/15/2024Novo Holdings A S1,307,829$17.55M1.2%N/A4.907%Search for SEC Filing on Google Icon
2/15/2024Omega Fund Management LLC2,157,623$28.96M23.5%N/A8.096%Search for SEC Filing on Google Icon
2/15/2024Blackstone Inc.696,110$9.34M0.0%N/A2.612%Search for SEC Filing on Google Icon
2/15/2024Citadel Advisors LLC2,084,245$27.97M0.0%N/A7.821%Search for SEC Filing on Google Icon
2/14/2024Cubist Systematic Strategies LLC25,750$0.35M0.0%N/A0.097%Search for SEC Filing on Google Icon
2/14/2024Verition Fund Management LLC189,062$2.54M0.0%N/A0.709%Search for SEC Filing on Google Icon
2/13/2024Northern Trust Corp15,589$0.21M0.0%N/A0.058%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Lexeo Therapeutics logo
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Read More on Lexeo Therapeutics

Today's Range

Now: $12.23
Low: $12.00
High: $12.83

50 Day Range

MA: $15.07
Low: $12.23
High: $17.00

52 Week Range

Now: $12.23
Low: $9.00
High: $22.33

Volume

44,755 shs

Average Volume

138,338 shs

Market Capitalization

$402.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Lexeo Therapeutics?

Lexeo Therapeutics' top insider investors include:
  1. Fund Vi LP Omega (Major Shareholder)
Learn More about top insider investors at Lexeo Therapeutics.